Loading organizations...
Innovent Biologics, based in Suzhou, China, develops, manufactures, and commercializes high-quality, affordable biologic medicines, primarily monoclonal antibodies and biosimilars. The company focuses on addressing unmet medical needs in oncology and other therapeutic areas, initially targeting China with global expansion goals. Revenue is generated from commercialized products such as Tyvyt (sintilimab), which received NMPA approval in China in December 2018. Innovent secured significant venture funding, including a $5 million Series A and a $260 million Series D, before listing on the Hong Kong Stock Exchange (1801 HK) in October 2018. The organization employs approximately 950 R&D staff as of end-2020 and maintains a key collaboration with Eli Lilly, with early investors including Fidelity Biosciences and Lilly Asia Ventures. Innovent Biologics was founded in August 2011 by Dr. Michael De-Chao Yu.
Innovent Biologics has raised $565.0M across 5 funding rounds.
Key people at Innovent Biologics.
Innovent Biologics was founded in 2011 by Michael Yu (Co-founder, CEO and President).
Innovent Biologics has raised $565.0M in total across 5 funding rounds.
Innovent Biologics has raised $565.0M across 5 funding rounds. Most recently, it raised $150.0M Series E in April 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 26, 2018 | $150M Series E | Nick Chen | Ally Bridge Group, Cormorant Asset Management, Hillhouse Capital Group, Legend Capital, Lilly Asia Ventures, Rock Springs Capital, Taikang, Temasek | Announced |
| Nov 29, 2016 | $260M Series D | Sdic Fund | Hillhouse Capital, Legend Capital, Milestone, Ping AN, Taikang, Temasek | Announced |
| Jan 1, 2015 | $120M Series C | Legend Capital | Creacion Ventures, Fidelity Growth Partners Asia, F Prime Capital, Frontline BioVentures, Lilly Asia Ventures, Temasek | Announced |
| Nov 1, 2012 | $30M Series B | — | Creacion Ventures | Announced |
| Sep 1, 2011 | $5M Series A | — | Creacion Ventures | Announced |
Innovent Biologics was founded in 2011 by Michael Yu (Co-founder, CEO and President).
Innovent Biologics has raised $565.0M in total across 5 funding rounds.
Innovent Biologics's investors include Nick Chen, Ally Bridge Group, Cormorant Asset Management, Hillhouse Capital Group, Legend Capital, Lilly Asia Ventures, Rock Springs Capital, Taikang, Temasek, SDIC Fund, Hillhouse Capital, Milestone.
Key people at Innovent Biologics.
Innovent Biologics is a leading biopharmaceutical company based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative antibody and protein medicines. It primarily serves patients with oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases by developing advanced biologic therapies such as monoclonal antibodies and antibody-drug conjugates (ADCs). The company addresses the significant unmet medical needs in China and beyond by providing high-quality, affordable biologics, demonstrating strong growth momentum with a robust and expanding product pipeline including marketed drugs like Tyvyt and BYVASDA, as well as novel candidates in late-stage development[1][2][4].
Founded in 2011 by Dr. Yu, Innovent Biologics emerged from the recognition of a large access gap to biologic medicines in China, where only about 6% of patients had access compared to over 90% in the U.S. Dr. Yu’s vision was to make life-changing biologic therapies widely available and affordable in China. Early on, the company focused on antibody drugs and biosimilars, rapidly building a diverse pipeline and advancing multiple candidates into clinical trials. Key milestones include launching China’s first IGF-1R antibody for thyroid eye disease and securing significant funding for R&D and global expansion, underscoring its evolution from a domestic innovator to a global biopharma contender[2][3].
Innovent Biologics rides the global trend of biologics and precision medicine transforming treatment paradigms, especially in oncology and autoimmune diseases. The timing is critical as biologics become standard-of-care worldwide, and China’s healthcare system increasingly supports innovative therapies. Market forces such as rising chronic disease prevalence, government support for biotech innovation, and growing patient demand favor Innovent’s growth. Its success influences the broader ecosystem by demonstrating that high-quality, affordable biologics can be developed domestically in China and compete globally, encouraging further innovation and investment in the region’s biopharma sector[2][4].
Looking ahead, Innovent Biologics is poised to deepen its global footprint through continued R&D investment, advancing novel therapies like bispecific antibodies and siRNA drugs. Trends shaping its journey include the rise of immuno-oncology, personalized medicine, and biologics manufacturing innovation. As it expands internationally, Innovent’s influence may grow as a model for bridging innovation and accessibility in emerging markets, potentially reshaping global biopharma competition. Its trajectory reflects a broader shift toward China as a major player in cutting-edge biotech innovation, fulfilling its founding mission to improve patient access to transformative medicines[2][4].
